Ophthalmologists at UC Davis Health used an experimental gene therapy last month to treat a patient with wet age-related macular degeneration, or wet AMD. It was the first time the UC Davis Eye Center had used gene therapy. The treatment was part of a randomized, partially masked, controlled, phase 3 clinical study evaluating the efficacy and safety of an experimental therapy, ABBV-RGX-314, for wet AMD. UC Davis Health is one of 93 sites in the U.S. participating in the clinical trial. This investigational treatment is not FDA approved, and the efficacy and safety have not been established.

https://www.miragenews.com/eye-center-trials-gene-therapy-for-wet-macular-1074008/

#miragenews